loading
Alnylam Pharmaceuticals Inc stock is traded at $236.73, with a volume of 287.37K. It is down -0.46% in the last 24 hours and up +42.88% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$237.83
Open:
$239.6
24h Volume:
287.37K
Market Cap:
$29.75B
Revenue:
$2.00B
Net Income/Loss:
$-332.08M
P/E Ratio:
-57.18
EPS:
-4.14
Net Cash Flow:
$127.82M
1W Performance:
-7.59%
1M Performance:
+42.88%
6M Performance:
+28.72%
1Y Performance:
+18.33%
1D Range:
Value
$234.16
$240.64
52W Range:
Value
$141.97
$263.73

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,100
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-08-01
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
SCHULMAN AMY W
Director
Jun 25 '24
Option Exercise
131.21
8,500
1,115,285
16,936
SCHULMAN AMY W
Director
Jun 25 '24
Sale
240.00
8,500
2,040,000
8,436
Greenstreet Yvonne
Chief Executive Officer
Jun 25 '24
Sale
230.99
8,301
1,917,475
80,534
Garg Pushkal
CMO & EVP Dev & Med Affairs
Jun 25 '24
Sale
230.99
2,103
485,773
15,609
Poulton Jeffrey V.
EVP, Chief Financial Officer
Jun 25 '24
Sale
231.00
1,605
370,747
28,892
Tanguler Tolga
EVP, Chief Commercial Officer
Jun 25 '24
Sale
231.00
1,605
370,747
11,660
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Jun 25 '24
Sale
230.99
1,198
276,731
14,181
PYOTT DAVID E I
Director
Jun 24 '24
Option Exercise
80.76
32,450
2,620,611
32,586
PYOTT DAVID E I
Director
Jun 24 '24
Sale
220.69
32,450
7,161,360
136
SCHULMAN AMY W
Director
May 29 '24
Option Exercise
66.83
30,000
2,004,900
30,136
$459.92
price down icon 2.37%
$86.33
price up icon 1.11%
$27.79
price up icon 0.11%
$159.08
price up icon 2.92%
$85.69
price up icon 1.91%
Cap:     |  Volume (24h):